These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 10456467)
1. New assay for measuring binding of platelet glycoprotein IIb/IIIa to unpurified von Willebrand factor. Veyradier A; Jumilly AL; Ribba AS; Obert B; Houllier A; Meyer D; Girma JP Thromb Haemost; 1999 Jul; 82(1):134-9. PubMed ID: 10456467 [TBL] [Abstract][Full Text] [Related]
2. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations. de Romeuf C; Hilbert L; Mazurier C Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349 [TBL] [Abstract][Full Text] [Related]
3. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease. Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386 [TBL] [Abstract][Full Text] [Related]
5. Shear stress-induced binding of von Willebrand factor to platelets. Konstantopoulos K; Chow TW; Turner NA; Hellums JD; Moake JL Biorheology; 1997; 34(1):57-71. PubMed ID: 9176590 [TBL] [Abstract][Full Text] [Related]
6. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease. Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443 [TBL] [Abstract][Full Text] [Related]
7. Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease. Hommais A; Stépanian A; Fressinaud E; Mazurier C; Pouymayou K; Meyer D; Girma JP; Ribba AS Thromb Haemost; 2006 May; 95(5):776-81. PubMed ID: 16676067 [TBL] [Abstract][Full Text] [Related]
8. Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations. Rastegar-Lari G; Ajzenberg N; Ribba AS; Vereycken-Holler V; Legendre P; Villoutreix B; Meyer D; Baruch D Thromb Haemost; 2001 Dec; 86(6):1459-65. PubMed ID: 11776314 [TBL] [Abstract][Full Text] [Related]
9. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease. Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885 [TBL] [Abstract][Full Text] [Related]
10. Evidence that the arg1744 gly1745 asp1746 sequence in the GPIIb-IIIa-binding domain of von Willebrand factor is involved in platelet adhesion and thrombus formation on subendothelium. Weiss HJ; Hoffmann T; Yoshioka A; Ruggeri ZM J Lab Clin Med; 1993 Sep; 122(3):324-32. PubMed ID: 8409708 [TBL] [Abstract][Full Text] [Related]
11. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467 [TBL] [Abstract][Full Text] [Related]
12. Influence of mutations and size of multimers in type II von Willebrand disease upon the function of von Willebrand factor. Christophe O; Ribba AS; Baruch D; Obert B; Rouault C; Niinomi K; Piétu G; Meyer D; Girma JP Blood; 1994 Jun; 83(12):3553-61. PubMed ID: 8204881 [TBL] [Abstract][Full Text] [Related]
13. Alteration in GPIIb/IIIa Binding of VWD-Associated von Willebrand Factor Variants with C-Terminal Missense Mutations. König G; Obser T; Marggraf O; Schneppenheim S; Budde U; Schneppenheim R; Brehm MA Thromb Haemost; 2019 Jul; 119(7):1102-1111. PubMed ID: 31035301 [TBL] [Abstract][Full Text] [Related]
14. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962 [TBL] [Abstract][Full Text] [Related]
15. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice--brief report. De Meyer SF; Schwarz T; Deckmyn H; Denis CV; Nieswandt B; Stoll G; Vanhoorelbeke K; Kleinschnitz C Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1949-51. PubMed ID: 20616311 [TBL] [Abstract][Full Text] [Related]
16. [Information on von Willebrand disease]. Nishino M; Fujimura Y Rinsho Byori; 1997 Oct; 45(10):942-50. PubMed ID: 9369071 [TBL] [Abstract][Full Text] [Related]
17. Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease. Chegeni R; Vickars L; Favaloro EJ; Lillicrap D; Othman M Thromb Res; 2011 Feb; 127(2):161-6. PubMed ID: 21094983 [TBL] [Abstract][Full Text] [Related]
18. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene. Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361 [TBL] [Abstract][Full Text] [Related]
19. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Gadisseur A; Berneman Z; Schroyens W; Michiels JJ Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359 [TBL] [Abstract][Full Text] [Related]
20. Inhibition assay for the binding of biotinylated von Willebrand factor to platelet-bound microtiter wells in the presence of ristocetin or botrocetin. Miura S; Nishida S; Makita K; Sakurai Y; Shimoyama T; Sugimoto M; Yoshioka A; Ishii K; Kito M; Kobayashi T; Fujimura Y Anal Biochem; 1996 May; 236(2):215-20. PubMed ID: 8660497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]